Literature DB >> 11115734

Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice.

A V Kuzmin1, M A Gerrits, E E Zvartau, J M van Ree.   

Abstract

The influence of different mixed mu-kappa-opioid receptor agonists-antagonists on cocaine reinforcement was studied using the method of initiation of intravenous cocaine self-administration in naive mice. Self-administration of cocaine was readily initiated according to an inverted U-shaped unit dose-response curve. Buprenorphine, butorphanol and nalbuphine tested against the optimal unit dose of cocaine (0.8 microg per infusion), inhibited initiation of cocaine self-administration in a dose-dependent manner. When tested against a scale of cocaine unit doses (0.2 -1.6 microg per infusion) buprenorphine (0.1 mg/kg, s.c.) and nalbuphine (2 mg/kg, s. c.) produced a shift of the optimal cocaine dose from 0.8 to 0.4 microg/inf, while butorphanol (1 mg/kg, s.c.) shifted the optimal unit dose of cocaine to the right along the cocaine unit doses axis. Co-administration of naloxone (0.1 mg/kg, s.c.) significantly reduced the effect of buprenorphine but failed to influence the effect of nalbuphine and butorphanol on cocaine intake. Taken together, these results suggest that nalbuphine is capable of affecting cocaine's reinforcing properties in the same manner as buprenorphine during the initiation phase of cocaine self-administration behavior, while butorphanol causes the opposite effect. Although the exact opioid profile of action of the mixed opioid receptor agonists-antagonists is as yet not precisely known, the present findings suggest that multiple opioid receptor systems (i.e. mu and kappa) play a role in reinforcing properties of cocaine and that a co-operative interaction between mu- and kappa-opioid systems may be of importance during initiation of cocaine self-administration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115734     DOI: 10.1016/s0924-977x(00)00117-6

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  7 in total

Review 1.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

2.  The effects of amphetamine, butorphanol, and their combination on cocaine self-administration.

Authors:  Mark A Smith; Michael M Pennock; Elizabeth G Pitts; Katherine L Walker; Kimberly C Lang
Journal:  Behav Brain Res       Date:  2014-08-12       Impact factor: 3.332

3.  Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.

Authors:  E C Eastwood; T J Phillips
Journal:  Genes Brain Behav       Date:  2013-11-18       Impact factor: 3.449

Review 4.  Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice.

Authors:  Heather Lyons Narver
Journal:  Lab Anim (NY)       Date:  2015-03       Impact factor: 12.625

5.  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Authors:  Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin
Journal:  J Nat Prod       Date:  2013-01-17       Impact factor: 4.050

6.  Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration.

Authors:  S Pons; L Fattore; G Cossu; S Tolu; E Porcu; J M McIntosh; J P Changeux; U Maskos; W Fratta
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

7.  Interactions Between Opioids and Dextroamphetamine on Locomotor Activity: Influence of an Opioid's Relative Efficacy at the Mu Receptor.

Authors:  Mark A Smith; Shannon L Ballard; Clarise F Ballesteros; Samantha A Bonge; Alexander T Casimir; Lauren M Childs; Max A Feinstein; Annie K Griffith; Alexandra N Johansen; Daegeon Lee; A Caroline Mauser; Cassidy M Moses; Ian J Robertson; Javier U Robles; Justin C Strickland; Mary E Walters; Seeley J Yoo
Journal:  Front Psychiatry       Date:  2022-01-05       Impact factor: 5.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.